Understanding CIS MS Diagnosis: Clinically Isolated Syndrome and its Relation to Multiple Sclerosis

Clinically Isolated Syndrome (CIS) can be a confusing and concerning experience. It represents the first time someone experiences neurological symptoms that could be suggestive of multiple sclerosis (MS). For those experiencing CIS, understanding what it means for their future health is paramount. This article provides a comprehensive overview of CIS, its diagnosis, and its connection to the potential development of MS.

What is Clinically Isolated Syndrome (CIS)?

Clinically Isolated Syndrome (CIS) is defined as the first episode of neurological symptoms caused by inflammation and demyelination in the central nervous system (CNS) – the brain and spinal cord. These symptoms must last for at least 24 hours and cannot be attributed to other causes like fever or infection. Think of it as a “warning sign” – the nervous system signaling distress.

While CIS is often the initial presentation of what might later be diagnosed as multiple sclerosis, it’s crucial to understand that not everyone who experiences CIS will develop MS. For some, CIS remains a single event without further neurological issues. For others, it’s the beginning of a relapsing-remitting or progressive form of MS.

Differentiating CIS from MS

The key difference between CIS and MS lies in the dissemination of lesions in time and space. MS diagnosis requires evidence of lesions (areas of damage) in the CNS that have occurred at more than one point in time and in more than one location. CIS, by definition, is a single episode.

If an MRI scan during a CIS event reveals multiple lesions characteristic of MS, it indicates damage in more than one location (dissemination in space). However, because it’s the first episode, there’s no documented evidence of these lesions occurring at different times (dissemination in time) – a requirement for a definitive MS diagnosis according to the McDonald Criteria.

Alt text: MRI scan visualizing white lesions in the brain, indicative of potential demyelination in Clinically Isolated Syndrome.

Causes of Clinically Isolated Syndrome

CIS arises from damage to myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord. This myelin damage, known as demyelination, disrupts the efficient transmission of electrical signals along the nerves. Imagine myelin as the insulation around an electrical wire; when the insulation is damaged, the signal becomes distorted or weakened.

The exact reasons why this demyelination occurs are still under investigation. It’s believed to be an autoimmune process, where the body’s immune system mistakenly attacks its own myelin. This inflammatory response leads to the neurological symptoms experienced in CIS.

Damage can occur in various locations within the CNS, leading to different types of CIS:

Monofocal CIS: Damage occurs in one area, resulting in a single symptom, such as optic neuritis.
Multifocal CIS: Damage occurs in multiple areas, leading to a combination of symptoms, like dizziness and bladder problems.

Diagnosing Clinically Isolated Syndrome: A Neurological Evaluation

Diagnosing CIS is a process of neurological assessment and ruling out other potential conditions. There isn’t a single test to definitively diagnose CIS. Instead, neurologists rely on a combination of factors:

1. Medical History: Uncovering Past Neurological Events

A detailed medical history is crucial. Neurologists will inquire about past symptoms that might have been overlooked. For instance, a previous episode of unexplained numbness or tingling, even if mild and transient, could be significant in the context of a current CIS event. These historical clues can sometimes indicate that the current CIS episode isn’t truly the first event, potentially pointing towards MS.

2. Neurological Examination: Assessing Nervous System Function

A comprehensive neurological examination is performed to assess various aspects of nervous system function. This includes:

Motor function: Strength, coordination, and reflexes.
Sensory function: Sensation to touch, pain, temperature, and vibration.
Vision: Visual acuity, eye movements, and visual fields.
Balance and coordination: Gait and balance tests.
Cognitive function: Mental status and cognitive abilities.

The findings from this examination help the neurologist determine if the symptoms are consistent with CNS dysfunction and pinpoint the areas of the nervous system potentially affected.

3. Blood Tests: Excluding Other Conditions

While there’s no blood test for CIS or MS itself, blood tests are essential to rule out other conditions that can mimic CIS symptoms. These conditions include infections, inflammatory disorders, and vitamin deficiencies. Excluding these alternatives is a critical step in reaching a CIS diagnosis.

4. MRI Scan: Visualizing Lesions in the CNS

Magnetic Resonance Imaging (MRI) is the most valuable diagnostic tool for CIS. MRI scans of the brain and spinal cord can detect lesions, or areas of damage, caused by demyelination. These lesions often appear as bright white spots on the MRI images.

Alt text: MRI scan highlighting a lesion in the spinal cord, potentially indicative of Transverse Myelitis in Clinically Isolated Syndrome.

Sometimes, a contrast agent called gadolinium is injected before the MRI. Gadolinium enhances the visibility of active inflammation, helping to differentiate between new, actively demyelinating lesions and older, inactive lesions.

The location, size, and number of lesions seen on the MRI are significant factors in assessing the risk of developing MS after CIS. Lesions in specific areas like the optic nerve, spinal cord, and brainstem are particularly relevant in CIS diagnosis.

Common Symptoms of Clinically Isolated Syndrome

The symptoms of CIS vary greatly depending on where the demyelination occurs in the CNS. Here are some of the most common symptoms:

1. Optic Neuritis: Inflammation of the Optic Nerve

Optic neuritis is a frequent symptom in CIS, resulting from damage to the optic nerve, which transmits visual information from the eye to the brain. Symptoms of optic neuritis can develop rapidly, over hours or days, and may include:

Eye pain: Often worsened by eye movement.
Blurred vision or vision loss: Can range from mild blurring to significant vision reduction, typically in one eye.
Color vision changes: Colors may appear less vivid or washed out.
Visual field defects: Blind spots or areas of reduced vision within the visual field.

It’s important to note that optic neuritis can occur as an isolated condition, and not everyone with optic neuritis will develop MS.

2. Transverse Myelitis: Spinal Cord Inflammation

Transverse myelitis occurs when demyelination affects the spinal cord. The onset of symptoms can be sudden (hours) or gradual (days to weeks). Symptoms depend on the level and extent of spinal cord involvement and can include:

Muscle weakness: In the legs, arms, or both.
Sensory disturbances: Numbness, tingling, burning sensations, or pain in the limbs or torso.
Bowel and bladder dysfunction: Urgency, frequency, incontinence, or constipation.

Like optic neuritis, transverse myelitis can also occur as an isolated event.

3. Lhermitte’s Sign: An Electrical Sensation

Lhermitte’s sign is a distinctive symptom often associated with demyelination in the spinal cord, particularly in the neck region. It’s characterized by a brief, electric shock-like sensation that travels down the back and sometimes into the limbs when the neck is flexed forward (chin to chest).

4. Brainstem Syndrome: Symptoms from Brainstem Damage

Brainstem syndrome arises from lesions in the brainstem, which controls vital functions. Symptoms are diverse and depend on the specific brainstem area affected. They can include:

Vertigo or dizziness: A sensation of spinning or imbalance.
Double vision (diplopia): Seeing two images of a single object.
Nausea and vomiting: Often associated with vertigo.
Facial weakness or numbness: Affecting one side of the face.
Difficulty swallowing or speaking: In some cases.

5. Other Symptoms: Fatigue and Cognitive Issues

Beyond these specific syndromes, other symptoms can accompany CIS, including:

Fatigue: Overwhelming tiredness that is not relieved by rest.
Cognitive difficulties: Problems with memory, concentration, attention, or processing speed.

Treatment Options for Clinically Isolated Syndrome

The approach to treating CIS depends on the severity of symptoms and the risk of developing MS.

1. Symptom Management: Addressing Acute Episodes

Many CIS episodes are mild and resolve spontaneously over weeks. However, for more severe symptoms, particularly optic neuritis or brainstem-related vertigo, high-dose corticosteroids (steroids) may be prescribed. Steroids can be given intravenously or orally for a short duration.

Steroids help reduce inflammation and can speed up recovery from acute CIS symptoms. However, they do not alter the long-term outcome or prevent the development of MS. Recovery will likely occur even without steroid treatment, but steroids can provide faster symptom relief.

2. Disease-Modifying Drugs (DMDs): Reducing MS Risk After CIS

For individuals considered at high risk of developing MS after CIS, neurologists may recommend disease-modifying drugs (DMDs). These medications are typically used to treat relapsing-remitting MS and have been shown to delay the conversion from CIS to clinically definite MS.

Risk factors that increase the likelihood of MS development after CIS include:

Presence of multiple lesions on MRI at baseline: More lesions at the time of CIS indicate a higher risk.
Lesions in specific locations: Brainstem and spinal cord lesions are associated with increased risk.
Older age at CIS onset: Older individuals with CIS have a higher conversion risk.
Oligoclonal bands in cerebrospinal fluid (CSF): These immune markers, detected through lumbar puncture, suggest increased MS risk.

DMDs for CIS typically include injectable interferon beta medications and glatiramer acetate. These drugs work by modulating the immune system to reduce inflammation and demyelination in the CNS. Starting DMD treatment after CIS can delay the onset of a second clinical episode and the diagnosis of MS.

Assessing the Risk of MS After CIS: Prognostic Factors

Predicting who will develop MS after CIS is not an exact science, but several factors help neurologists assess individual risk:

MRI findings: The most powerful predictor is the presence and number of lesions on the initial MRI scan.
Age: Older individuals at CIS onset are at higher risk.
Oligoclonal bands: Presence in CSF increases risk.
Symptoms during CIS: While less predictive than MRI, certain symptoms may be associated with slightly higher risk.

It’s important to discuss your individual risk factors with your neurologist to understand your personal prognosis.

Lifestyle Factors and CIS to MS Conversion

While DMDs target the underlying disease process, lifestyle modifications can also play a supportive role in overall health and potentially influencing MS risk after CIS.

Smoking cessation: Smoking is linked to a higher risk of MS conversion in people with CIS. Quitting smoking is strongly recommended.
Vitamin D levels: Low vitamin D levels have been associated with increased MS risk. Maintaining adequate vitamin D levels through sunlight exposure, diet, or supplementation may be beneficial, although more research is needed to confirm the effectiveness of supplementation in preventing MS conversion.
Healthy diet and exercise: Maintaining a healthy weight, eating a balanced diet, and engaging in regular physical activity are generally beneficial for overall health and may indirectly support neurological health.

Living with CIS: Managing Uncertainty

Living with CIS can be emotionally challenging due to the uncertainty about the future. The possibility of developing MS can cause anxiety, fear, and stress. It’s important to acknowledge these feelings and seek support.

Information and education: Understanding CIS and MS can empower individuals to make informed decisions and reduce anxiety related to the unknown.
Support networks: Connecting with others who have CIS or MS through support groups or online communities can provide valuable peer support and shared experiences.
Mental health support: If anxiety or depression are significant, seeking professional help from a therapist or counselor can be beneficial.
Regular follow-up with neurology team: Consistent communication with your neurologist is crucial for monitoring your condition, addressing new symptoms, and making informed decisions about treatment and lifestyle management.

Radiologically Isolated Syndrome (RIS): Lesions Without Symptoms

It’s worth mentioning Radiologically Isolated Syndrome (RIS). RIS is diagnosed when MRI scans performed for other reasons (like headaches or trauma) incidentally reveal brain or spinal cord lesions suggestive of MS in someone who has never experienced neurological symptoms. While distinct from CIS (which involves symptoms), RIS also carries an increased risk of developing MS over time and is often monitored by neurologists.

Conclusion: CIS as a Crossroads

Clinically Isolated Syndrome represents a crucial point in neurological health. It’s a first warning sign that requires careful evaluation and management. While CIS can be the first step towards MS for some, it’s not a guaranteed path. Understanding the diagnosis process, symptom management, risk factors, and treatment options empowers individuals to navigate this uncertain period. Early diagnosis, informed decision-making regarding treatment, and proactive lifestyle choices can play a significant role in influencing the long-term neurological health of individuals experiencing CIS. If you suspect you may have experienced CIS, seeking prompt medical evaluation by a neurologist is essential for accurate diagnosis and appropriate management.

References

Miller D, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurology 2005;4(5):281-288. Summary (link is external)
D’Alessandro R, et al. Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study. Journal of Neurology 2013;260(6):1583-1593. Summary (link is external)
Kappos L, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67(7):1242-1249. Summary (link is external)
Comi G, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374(9700):1503-1511. Summary (link is external)
Association of British Neurologists (ABN). Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Practical Neurology 2015;15(4):273-279. Full guideline (link is external)
Fisniku LK, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131(3):808-817. Summary (link is external)
Polman CH, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald Criteria. Annals of Neurology 2011;69(2):292-302. Summary (link is external)
Montalban X, et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010;74(5):427-434. Summary (link is external)
Scalfari A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010;133(7):1914-1929. Summary (link is external)
Gal RL, et al. Corticosteroids for treating optic neuritis. Cochrane Database of Systematic Reviews 2012;4:CD001430. Summary (link is external)
Scott TF, et al. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011;77(24):2128-2134. Summary (link is external)
Confavreux C, Vukusic S. Natural history of MS: a unifying concept. Brain 2006;129(3):606-616. Summary (link is external)
Taylor BV, et al. Latitudinal variation in incidence and type of first central nervous system demyelinating events. Multiple Sclerosis 2010;16(4):398-405. Summary (link is external)
Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Archives of Neurology 2008;65(6):727-732. Summary (link is external)
Tintoré M, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008;70(13 pt2):1079-1083. Summary (link is external)
Tintoré M, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006;67(6):968-972. Summary (link is external)
Rojas JI, et al. Oligoclonal bands and MRI in clinically isolated syndromes: predicting conversion time to multiple sclerosis. Journal of Neurology 2010;257(7):1188-1191. Summary (link is external)
Jacobs LD, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. New England Journal of Medicine 2000;343(13):898-904. Summary (link is external)
Comi G, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357(9268):1576-1582. Summary (link is external)
Comi G. Clinically isolated syndrome: the rationale for early treatment. Nature Clinical Practice. Neurology 2008;4(5):234-235.
Montalban X, Sastre-Garriga J. Diagnosis and trials of clinically isolated syndrome. Lancet Neurology 2014;13(10):962-963.
Miller DH, et al. Clinically isolated syndromes. Lancet Neurology 2012;11(2):157-169. Summary (link is external)
Grzegorski T, Losy J. What do we currently know about the clinically isolated syndrome suggestive of multiple sclerosis? An update. Reviews in the Neurosciences 2019; Dec 7 [Epub ahead of print]. Summary (link is external)
Rintala A, et al. Emotional outcomes in clinically isolated syndrome and early phase multiple sclerosis: a systematic review and meta-analysis. Journal of Psychosomatic Research 2019;124:109761. Summary (link is external)
Miller AE, et al. Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: results of the TOPIC extension study. Multiple Sclerosis and Related Disorders 2019;33:131-138. Full article (link is external)
Metz LM. Clinically isolated syndrome and early relapsing multiple sclerosis. Continuum (Mineapp Minn) 2019;25(3):670-688. Summary (link is external)
Hartung HP, et al. Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study. Journal of Neurology 2019; Jan 4 [Epub ahead of print] Summary (link is external)
Gaetani L, et al. 2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. Journal of Neurology 2018;265(11):2684-2687. Summary (link is external)
Eran A, et al. MRI in predicting conversion to multiple sclerosis within 1 year. Brain and Behavior 2018;8(9):e01042. Full article (link is external)
Shaheen HA, et al. Does vitamin D deficiency predict early conversion of clinically isolated syndrome? A preliminary Egyptian study. International Journal of Neuroscience 2018;128(10):946-951. Summary (link is external)
van der Vuurst de Vries RM, et al. Smoking at time of CIS increases the risk of clinically definite multiple sclerosis. Journal of Neurology 2018; 265(5):1010-1015. Full article (link is external)
Armoiry X, et al. Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis. Journal of Neurology 2018;265(5):999-1009. Full article (link is external)
O’Connell K, et al. Effects of vitamin D3 in clinically isolated syndrome and healthy control participants: a double-blind randomised controlled trial. Multiple Sclerosis Journal – Experimental, Translational and Clinical 2017;3(3): 20555217317727296. Full article (link is external)
van der Vuurst de Vries RM, et al. Fatigue after a first attack of suspected multiple sclerosis. Multiple Sclerosis 2018;24(7):974-981. Full article (link is external)
Kappos L, et al. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology 2016;87(10):978-987. Full article (link is external)
Pokryszko-Dragan A, et al. Cognitive performance, fatigue and event-related potentials in patients with clinically isolated syndrome. Clinical Neurology and Neurosurgery 2016;149:68-74. Summary (link is external)
Borràs E, et al. Protein-based classifier to predict conversion from clinically isolated syndrome to multiple sclerosis. Molecular and Cellular Proteomics 2016;15(1):318-328. Full article (link is external)
Kuhle J, et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Multiple Sclerosis 2015;21(8):1013-1024. Summary (link is external)